WO2020052575A1 - Utilisation d'une combinaison d'un inhibiteur de kinase jak et d'un inhibiteur d'egfr dans la préparation d'un médicament pour le traitement de maladies tumorales - Google Patents

Utilisation d'une combinaison d'un inhibiteur de kinase jak et d'un inhibiteur d'egfr dans la préparation d'un médicament pour le traitement de maladies tumorales Download PDF

Info

Publication number
WO2020052575A1
WO2020052575A1 PCT/CN2019/105250 CN2019105250W WO2020052575A1 WO 2020052575 A1 WO2020052575 A1 WO 2020052575A1 CN 2019105250 W CN2019105250 W CN 2019105250W WO 2020052575 A1 WO2020052575 A1 WO 2020052575A1
Authority
WO
WIPO (PCT)
Prior art keywords
day
cancer
formula
pharmaceutically acceptable
egfr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2019/105250
Other languages
English (en)
Chinese (zh)
Inventor
唐蜜
邓智临
廖成
杨昌永
张连山
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Priority to CN201980052669.6A priority Critical patent/CN112533606B/zh
Publication of WO2020052575A1 publication Critical patent/WO2020052575A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the disclosure belongs to the field of medicine, and relates to the use of a combination of a JAK kinase inhibitor and a human epidermal growth factor receptor inhibitor (EGFRi) in the preparation of a medicament for preventing or treating a tumor disease.
  • EGFRi human epidermal growth factor receptor inhibitor
  • Non-small cell lung cancer accounts for about 85% of all lung cancers, and about 75% of NSCLC patients are in the middle and advanced stages at the time of discovery, and the 5-year survival rate is very low. For patients with advanced or metastatic NSCLC, there is still a great clinical need to choose appropriate systemic treatments.
  • NSCLC can be divided into squamous cell carcinoma and non-squamous cell carcinoma.
  • Non-squamous cell carcinoma includes adenocarcinoma, large cell carcinoma, and other subtypes of cell carcinoma.
  • Non-squamous cell carcinoma patients were further classified according to the presence or absence of a driver mutation gene (EGFR mutation or ALK gene rearrangement).
  • EGFR Epidermal Growth Factor Receptor
  • EGF epidermal growth factor
  • EGFR can form homodimers on the cell membrane or form heterodimers with other receptors in the family (such as erbB2, erbB3, or erbB4).
  • the formation of these dimers can cause phosphorylation of key tyrosine residues in EGFR cells, thereby activating multiple downstream signaling pathways in the cell. These intracellular signaling pathways play important roles in cell proliferation, survival, and anti-apoptosis.
  • Imbalanced EGFR signaling pathways can promote the transformation of cells to malignancy and play an important role in tumor cell proliferation, invasion, metastasis, and angiogenesis.
  • EGFR overexpression has been reported in many human malignant diseases, including bladder cancer, brain tumor, head and neck cancer, pancreatic cancer, lung cancer, breast cancer, ovarian cancer, colon cancer, prostate cancer, and kidney cancer. In many cases, overexpression of EGFR is associated with poor prognosis in patients.
  • JAK Janus kinase
  • JAK1 JAK2
  • JAK3 JAK3
  • JAK3 can specifically and non-covalently bind to the gamma chain (Fc ⁇ ) shared by cytokine receptors, while JAK1 binds to the beta chain.
  • the two are IL-2, IL-4, IL-7, IL-9, and IL-9.
  • IL-15 cytokines JAK2 plays an important role in the erythropoietin (EPO) signaling pathway, including erythrocyte differentiation and activation of signal transduction and activator of transcription (STAT).
  • EPO erythropoietin
  • JAK-STAT signal transduction pathway is a chain in cells that interacts with proteins and is involved in, for example, process immunity, cell division, cell death, and tumor formation. This pathway passes information from extracellular chemical signals to the nucleus, thereby activating genes through a process called transcription.
  • JAK-STAT signaling There are three key components of JAK-STAT signaling: Janus kinase (JAK), signal transduction and transcription protein activating factors (STATs), and receptors (binding chemical signals).
  • JAK-STAT signaling can cause a variety of diseases, such as skin diseases, cancer, and disorders affecting the immune system (Science.296 (5573): 1653-5).
  • JAK-STAT signaling can allow the transcription of genes involved in cell division
  • one potential effect of excessive JAK-STAT signaling is cancer formation.
  • High levels of STAT activation are associated with cancer.
  • STAT3 and STAT5 activations are mainly associated with more dangerous tumors (British Journal of Cancer. 113 (3): 365–371.).
  • JAK-STAT Signaling through the JAK-STAT (Signal Transduction and Transcription Activator) pathway may be a factor in the resistance of EGFR-mutant NSCLC patients to EGFR TKI therapy. Therefore, blocking JAK and EGFR activity may provide improved targeted therapy benefits in some patients.
  • the prior art discloses the combination of some CDK kinase inhibitors and EGFR kinase inhibitors. Specifically, the document Synergistic anti-tumor effect of combined EGFR and JAK / STAT3 pathways in humans.
  • a JAK2 inhibitor AZD1480 is disclosed in human ovarian cancer The combination of gefitinib showed a synergistic effect on the treatment of ovarian cancer.
  • WO2013091539 provides an effective JAK kinase inhibitor, the structure of which is shown in Formula I, and WO2014194741 discloses the bisulfate salt of JAK kinase inhibitor shown in Formula I,
  • WO2016054987A discloses a 4-substituted-2- (N- (5-allylamido) phenyl) amino) pyrimidine derivative having the structure shown in formula (II).
  • the compound has the ability to inhibit L858R, EGFR mutant, and T790M.
  • the EGFR mutant and exon 19 deletion activate the activity of the mutant and can be used to treat diseases mediated by EGFR mutant activity alone or in part.
  • WO2017161937 discloses a mesylate salt of an EGFR inhibitor represented by formula (II),
  • the present disclosure provides the use of a new JAK kinase inhibitor combined with an EGFR inhibitor in the manufacture of a medicament for preventing or treating non-small cell lung cancer.
  • the present disclosure provides a use of a JAK kinase inhibitor and an EGFR inhibitor in the manufacture of a medicament for preventing or treating a tumor disease.
  • the tumor diseases described in the present disclosure are selected from breast cancer, ovarian cancer, prostate cancer, melanoma, brain tumor, esophageal cancer, gastric cancer, liver cancer, pancreatic cancer, colorectal cancer, lung cancer, kidney cancer, skin cancer, glioblastoma , Neuroblastoma, sarcoma, liposarcoma, osteochondroma, osteoma, osteosarcoma, seminoma, testicular tumor, uterine cancer, head and neck tumor, multiple myeloma, malignant lymphoma, polycythemia vera, leukemia , Thyroid tumor, ureter tumor, bladder tumor, gallbladder cancer, non-small cell lung cancer, bile duct cancer or chorionic epithelial cancer, preferably non-small cell lung cancer.
  • the EGFR-mutated tumor disease described in the present disclosure is preferably non-small cell lung cancer, and the preferred EGFR mutant is selected from L858R EGFR mutant and / or T790M EGFR mutant.
  • the non-small cell lung cancer described in the present disclosure is selected from squamous cell carcinoma and non-squamous cell carcinoma, preferably non-phosphorous cell carcinoma, wherein the non-phosphorous cell carcinoma may be adenocarcinoma, large cell carcinoma and Other subtypes of cell carcinoma.
  • the JAK kinase inhibitor is selected from the group consisting of PF-06826647, tofacitinib, SNA-125, TD-1473, upadacitinib, ilginatinib, maleate, peficitinib, momomelotinib, panobinostat, AZD-4205, itacitinib, baricitinib, ganetespib, filgotinib, BMS-986165, PF-06700841, PF-04965842, ATI-502, ATI-501, pacritinib, ruxolitinib, WP-1066, ASN-002, INCB-054707, cerdulatinib, TG-02, fedratinib, INCB-52793, PF-06651600, ENMD-2076, TD-3504, delgocitinib, vidofludimus, delgocitinib, R-348 or a compound
  • the EGFR inhibitor is selected from the group consisting of osimertinib, gefitinib, erlotinib, olmutinib, icotinib, pyrotinib, vandetanib, brigatinib, dacomitinib, afatinib, neratinib, lapatinib, ABT-414, varlitinib, HLX-07, tesevatinib, theliatinib, epitinib, succinate, S-222611, poziotinib, AST-2818, GNS-1480, mavelertinib, AP-32788, AZD-3759, josartinib, Sym-013, tesevatinib, allitinib tosylate, tarloxotinib, bromide, poziotinib, CK-101, QL -1203, J
  • the dose of the JAK kinase inhibitor is selected from 1-1000 mg, and the EGFR inhibitor is 1-1000 mg.
  • the dosage of the JAK kinase inhibitor described in the present disclosure is selected from the present disclosure
  • the dosage of the EGFR inhibitor described in the present disclosure is selected from 1 mg, 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg, 17.5 mg, 20 mg, 22.5 mg, 25 mg, 27.5 mg, 30 mg, 32.5 mg, 35 mg, 37.5 mg, 40mg, 42.5mg, 45mg, 47.5mg, 50mg, 52.5mg, 55mg, 60mg, 65mg, 70mg, 75mg, 80mg, 85mg, 90mg, 95mg, 100mg, 105mg, 110mg, 120mg, 130mg, 140mg, 150mg, 160mg , 170mg, 180mg, 190mg, 200mg, 210mg, 220mg, 230mg, 240mg, 250mg, 260mg, 270mg, 280mg, 290mg, 300mg, 350mg, 400mg, 450mg, 500mg, 550m
  • the dose of the JAK kinase inhibitor is selected from 1-1000 mg
  • the frequency of administration may be once a day, twice a day, or three times a day
  • the dose of the EGFR inhibitor is selected from 1-1000 mg
  • the frequency of administration can be once a day, twice a day, or three times a day.
  • the dose of the JAK kinase inhibitor is selected from 1 to 600 mg, the frequency of administration may be once a day or twice a day, and the dose of the EGFR inhibitor is selected from 1 to 500 mg, the frequency of administration It is once a day.
  • the dose of the JAK kinase inhibitor is selected from 1-200 mg, the frequency of administration may be once a day or twice a day, and the dose of the EGFR inhibitor is selected from 1-500 mg, the frequency of administration It is once a day.
  • the dose of the JAK kinase inhibitor is selected from 1-100 mg
  • the frequency of administration may be once a day or twice a day
  • the dose of the EGFR inhibitor is selected from 1-500 mg
  • the frequency of administration It is once a day.
  • the dose of the JAK kinase inhibitor is selected from 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 11 mg, 12 mg, 13 mg, 14 mg, 15 mg, 16 mg, 17 mg, 18mg, 19mg, 20mg, 21mg, 22mg, 23mg, 24mg, 25mg, 26mg, 27mg, 28mg, 29mg, 30mg, 31mg, 32mg, 33mg, 34mg, 35mg, 36mg, 37mg, 38mg, 39mg, 40mg, 41mg, 42mg, 43mg, 44mg, 45mg, 46mg, 47mg, 48mg, 49mg, 50mg, the frequency of administration is once a day or twice a day, the dose of the EGFR inhibitor is selected from 55mg, 110mg, 220mg, 260mg, the frequency of administration is Once a
  • the dose of the JAK kinase inhibitor is selected from 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 11 mg, 12 mg, 13 mg, 14 mg, 15 mg, 16 mg, 17 mg, 18mg, 19mg, 20mg, the frequency of administration is once a day or twice a day, the dose of the EGFR inhibitor is selected from 55mg, 110mg, 220mg, 260mg, and the frequency of administration is once a day.
  • the dose of the JAK kinase inhibitor is selected from 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, and the frequency of administration is once a day or twice a day.
  • the dose of the EGFR inhibitor is selected from 55 mg, 110 mg, 220 mg, and 260 mg, and the frequency of administration is once a day.
  • the dose of the JAK kinase inhibitor is selected from 1 mg, 2 mg, 4 mg, 6 mg, and 8 mg, the frequency of administration is once a day or twice a day, and the dose of the EGFR inhibitor is selected from 55 mg, 110mg, 220mg, 260mg, the frequency of administration is once a day.
  • the JAK kinase inhibitor is a compound represented by formula (I) or a stereoisomer, complex, or a pharmaceutically acceptable salt thereof.
  • the JAK kinase inhibitor is a compound represented by formula (I) or a stereoisomer, complex or pharmaceutically acceptable salt thereof, wherein the compound represented by formula (I) or a stereoisomer thereof
  • the dose of the EGFR, complex or pharmaceutically acceptable salt thereof is selected from 1-1000 mg, and the frequency of administration may be once a day, twice a day, or three times a day.
  • the dose of the EGFR inhibitor is selected from 1-1000 mg.
  • the frequency of the drug can be once a day, twice a day, or three times a day.
  • the JAK kinase inhibitor is a compound represented by formula (I) or a stereoisomer, complex or pharmaceutically acceptable salt thereof, wherein the compound represented by formula (I) or a stereoisomer thereof
  • the dose of the EGFR, complex or pharmaceutically acceptable salt thereof is selected from 1 to 200 mg, and the frequency of administration may be once a day or twice a day.
  • the dose of the EGFR inhibitor is selected from 1 to 500 mg, and the frequency of administration is one day. once.
  • the JAK kinase inhibitor is a compound represented by formula (I) or a stereoisomer, complex or pharmaceutically acceptable salt thereof, wherein the compound represented by formula (I) or a stereoisomer thereof
  • the dose of the body, complex or pharmaceutically acceptable salt thereof is selected from 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 11 mg, 12 mg, 13 mg, 14 mg, 15 mg, 16 mg, 17 mg, 18 mg, 19mg, 20mg, 21mg, 22mg, 23mg, 24mg, 25mg, 26mg, 27mg, 28mg, 29mg, 30mg, 31mg, 32mg, 33mg, 34mg, 35mg, 36mg, 37mg, 38mg, 39mg, 40mg, 41mg, 42mg, 43mg, 44mg, 45mg, 46mg, 47mg, 48mg, 49mg, 50mg,
  • the JAK kinase inhibitor is a compound represented by formula (I) or a stereoisomer, complex or pharmaceutically acceptable salt thereof, wherein the compound represented by formula (I) or a stereoisomer thereof
  • the dose of the body, complex or pharmaceutically acceptable salt thereof is selected from 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 11 mg, 12 mg, 13 mg, 14 mg, 15 mg, 16 mg, 17 mg, 18 mg, 19mg, 20mg, the frequency of administration can be once a day or twice a day, the dose of the EGFR inhibitor is selected from 55mg, 110mg, 220mg, 260mg, and the frequency of administration is once a day.
  • the JAK kinase inhibitor is a compound represented by formula (I) or a stereoisomer, complex or pharmaceutically acceptable salt thereof, wherein the compound represented by formula (I) or a stereoisomer thereof
  • the dosage of the body, complex or pharmaceutically acceptable salt thereof is selected from 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, and the frequency of administration may be once a day or twice a day.
  • the EGFR inhibitor dose is selected from 55 mg, 110 mg, 220 mg, and 260 mg, and the frequency of administration is once a day.
  • the JAK kinase inhibitor is a compound represented by formula (I) or a stereoisomer, complex or pharmaceutically acceptable salt thereof, wherein the compound represented by formula (I) or a stereoisomer thereof
  • the dose of the EGFR, complex or pharmaceutically acceptable salt thereof is selected from 1 mg, 2 mg, 4 mg, 6 mg, and 8 mg, and the frequency of administration may be once a day or twice a day.
  • the dose of the EGFR inhibitor is selected from 55 mg, 110 mg, 220mg, 260mg, dosing frequency is once a day.
  • the EGFR inhibitor is a compound of formula (II) or a stereoisomer, complex or pharmaceutically acceptable salt thereof.
  • the dose of the JAK kinase inhibitor is selected from 1-1000 mg
  • the frequency of administration may be once a day, twice a day, or three times a day
  • the EGFR inhibitor is a compound of formula (II) Or a stereoisomer, complex or pharmaceutically acceptable salt thereof, wherein the dose of the compound of formula (II) or a stereoisomer, complex or pharmaceutically acceptable salt thereof is selected from 1 to 1000 mg
  • the frequency of administration may be Once a day, twice a day, or three times a day.
  • the dose of the JAK kinase inhibitor is selected from 1-200 mg
  • the frequency of administration may be once a day or twice a day
  • the EGFR inhibitor is a compound of formula (II) or a steric Structure, complex or pharmaceutically acceptable salt thereof, wherein the dose of the compound of formula (II) or its stereoisomer, complex or pharmaceutically acceptable salt is selected from 1-500 mg, and the frequency of administration may be once a day or Twice a day.
  • the dose of the JAK kinase inhibitor is selected from 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 11 mg, 12 mg, 13 mg, 14 mg, 15 mg, 16 mg, 17 mg , 18mg, 19mg, 20mg, 21mg, 22mg, 23mg, 24mg, 25mg, 26mg, 27mg, 28mg, 29mg, 30mg, 31mg, 32mg, 33mg, 34mg, 35mg, 36mg, 37mg, 38mg, 39mg, 40mg, 41mg, 42mg , 43mg, 44mg, 45mg, 46mg, 47mg, 48mg, 49mg, 50mg, the frequency of administration may be once a day or twice a day, the EGFR inhibitor is a compound of formula (II) or a stereoisomer, a compound thereof Or a pharmaceutically acceptable salt
  • the dose of the JAK kinase inhibitor is selected from 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 11 mg, 12 mg, 13 mg, 14 mg, 15 mg, 16 mg, 17 mg , 18mg, 19mg, 20mg, the frequency of administration may be once a day or twice a day
  • the EGFR inhibitor is a compound of formula (II) or a stereoisomer, a complex or a pharmaceutically acceptable salt thereof, wherein (II)
  • the dose of the compound or its stereoisomer, complex or pharmaceutically acceptable salt is selected from 55 mg, 110 mg, 220 mg, and 260 mg, and the frequency of administration is once a day.
  • the dose of the JAK kinase inhibitor is selected from 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, and 10 mg, and the frequency of administration may be once a day or twice a day.
  • the EGFR inhibitor is a compound of formula (II) or a stereoisomer, complex or pharmaceutically acceptable salt thereof, wherein the compound of formula (II) or a stereoisomer, complex or pharmaceutically acceptable salt thereof is The dose is selected from 55mg, 110mg, 220mg, 260mg, and the frequency of administration is once a day.
  • the dose of the JAK kinase inhibitor is selected from 1 mg, 2 mg, 4 mg, 6 mg, and 8 mg, and the frequency of administration may be once a day or twice a day.
  • the EGFR inhibitor is of formula (II ) Compound or stereoisomer, complex or pharmaceutically acceptable salt thereof, wherein the dose of the compound of formula (II) or stereoisomer, complex or pharmaceutically acceptable salt thereof is selected from 55 mg, 110 mg, 220 mg, 260 mg The dosing frequency is once a day.
  • the JAK kinase inhibitor is a compound represented by formula (I) or a stereoisomer, a complex or a pharmaceutically acceptable salt thereof
  • the EGFR inhibitor is a compound of formula (II) or a Stereoisomers, complexes or pharmaceutically acceptable salts thereof.
  • the JAK kinase inhibitor is a compound represented by formula (I) or a stereoisomer, a complex or a pharmaceutically acceptable salt thereof
  • the EGFR inhibitor is a compound of formula (II) or a Stereoisomers, complexes or pharmaceutically acceptable salts thereof, wherein the dose of the compound represented by formula (I) or a stereoisomers, complexes or pharmaceutically acceptable salts thereof is selected from 1-1000 mg, and the frequency of administration may be one
  • the dose of the compound of formula (II) or its stereoisomers, complexes or pharmaceutically acceptable salts is selected from 1-1000 mg once a day, twice a day, or three times a day. Two times or three times a day.
  • the JAK kinase inhibitor is a compound represented by formula (I) or a stereoisomer, a complex or a pharmaceutically acceptable salt thereof
  • the EGFR inhibitor is a compound of formula (II) or a Stereoisomers, complexes or pharmaceutically acceptable salts thereof, wherein the dose of the compound represented by formula (I) or a stereoisomers, complexes or pharmaceutically acceptable salts thereof is selected from 1 to 200 mg, and the frequency of administration may be one
  • the dose of the compound of formula (II) or a stereoisomer, complex or pharmaceutically acceptable salt thereof is selected from 1 to 500 mg once a day or twice a day.
  • the JAK kinase inhibitor is a compound represented by formula (I) or a stereoisomer, a complex or a pharmaceutically acceptable salt thereof
  • the EGFR inhibitor is a compound of formula (II) or a Stereoisomers, complexes or pharmaceutically acceptable salts thereof, wherein the dose of the compound represented by formula (I) or a stereoisomers, complexes or pharmaceutically acceptable salts thereof is selected from 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 6mg, 7mg, 8mg, 9mg, 10mg, 11mg, 12mg, 13mg, 14mg, 15mg, 16mg, 17mg, 18mg, 19mg, 20mg, 21mg, 22mg, 23mg, 24mg, 25mg, 26mg, 27mg, 28mg, 29mg, 30mg, 31mg, 32mg, 33mg, 34mg, 35mg, 36mg, 37mg
  • the JAK kinase inhibitor is a compound represented by formula (I) or a stereoisomer, a complex or a pharmaceutically acceptable salt thereof
  • the EGFR inhibitor is a compound of formula (II) or a Stereoisomers, complexes or pharmaceutically acceptable salts thereof
  • the dose of the compound represented by formula (I) or a stereoisomers, complexes or pharmaceutically acceptable salts thereof is selected from 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 6mg, 7mg, 8mg, 9mg, 10mg, 11mg, 12mg, 13mg, 14mg, 15mg, 16mg, 17mg, 18mg, 19mg, 20mg
  • the frequency of administration can be once a day or twice a day
  • the compound of formula (II) or The dosage of the stereoisomer, complex or pharmaceutically acceptable salt thereof is selected from 55mg, 110mg, 220mg, 260mg, and the frequency of administration
  • the JAK kinase inhibitor is a compound represented by formula (I) or a stereoisomer, a complex or a pharmaceutically acceptable salt thereof
  • the EGFR inhibitor is a compound of formula (II) or a Stereoisomers, complexes or pharmaceutically acceptable salts thereof, wherein the dose of the compound represented by formula (I) or a stereoisomers, complexes or pharmaceutically acceptable salts thereof is selected from 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 6mg, 7mg, 8mg, 9mg, 10mg, the frequency of administration can be once a day or twice a day, the dose of the compound of formula (II) or its stereoisomers, complexes or pharmaceutically acceptable salts is selected from 55mg, 110mg, 220mg, 260mg, the frequency of administration is once a day.
  • the JAK kinase inhibitor is a compound represented by formula (I) or a stereoisomer, a complex or a pharmaceutically acceptable salt thereof
  • the EGFR inhibitor is a compound of formula (II) or a Stereoisomers, complexes or pharmaceutically acceptable salts thereof, wherein the dose of the compound represented by formula (I) or a stereoisomers, complexes or pharmaceutically acceptable salts thereof is selected from 1 mg, 2 mg, 4 mg, 6 mg, 8 mg, The frequency of administration may be once a day or twice a day.
  • the dose of the compound of formula (II) or its stereoisomers, complexes or pharmaceutically acceptable salts is selected from 55 mg, 110 mg, 220 mg, and 260 mg. Once a day.
  • the pharmaceutically acceptable salts of the drugs described in this disclosure may be hydrochloride, phosphate, hydrogen phosphate, sulfate, hydrogen sulfate, sulfite, acetate, oxalate, malonate, valerate , Glutamate, oleate, palmitate, stearate, laurate, borate, p-toluenesulfonate, mesylate, isethionate, maleate, Malate, tartrate, benzoate, paraben, salicylate, vanillate, mandelate, succinate, gluconate, lactobionate or laurylsulfonate.
  • the pharmaceutically acceptable salt of the compound represented by formula (I) is a hydrogen sulfate salt.
  • the pharmaceutically acceptable salt of the compound represented by formula (II) is a mesylate salt.
  • the combined administration of the present disclosure includes oral administration, parenteral administration, and transdermal administration.
  • the parenteral administration includes, but is not limited to, intravenous injection, subcutaneous injection, intramuscular injection, and preferably oral administration. .
  • the present disclosure also provides a pharmaceutical composition of the aforementioned JAK kinase inhibitor and EGFR inhibitor, and one or more pharmaceutically acceptable carriers, excipients, and diluents.
  • the pharmaceutical composition can be made into any pharmaceutically acceptable dosage form. For example, they can be formulated as tablets, capsules, pills, granules, solutions, suspensions, syrups, injections (including injections, sterile powders for injections and concentrated solutions for injections), suppositories, inhalants or sprays Agent.
  • the present disclosure also provides a method for treating a tumor disease, comprising administering to a patient an effective amount of the aforementioned JAK kinase inhibitor and an effective amount of the aforementioned EGFR inhibitor.
  • the present disclosure also provides a pharmaceutical kit for use in a medicament for treating a tumor disease, in which a pharmaceutical composition of the JAK kinase inhibitor and the EGFR inhibitor described in the present disclosure is packaged.
  • the present disclosure combines the administration of a JAK kinase inhibitor and an EGFR inhibitor, thereby enhancing the effect in a medicine for treating a tumor disease.
  • the "combination" described in the present disclosure is a mode of administration, which means that at least one dose of a JAK kinase inhibitor and at least one dose of an EGFR inhibitor are administered within a certain period of time, both of which show pharmacology ⁇ Role.
  • the time period may be within one administration cycle, preferably within 4 weeks, within 3 weeks, within 2 weeks, within 1 week, or within 24 hours, more preferably within 12 hours.
  • the JAK kinase inhibitor and the EGFR inhibitor may be administered simultaneously or sequentially. This term includes treatments in which JAK kinase inhibitors and EGFR inhibitors are administered by the same route or different routes of administration.
  • Figure 1 The efficacy of the compound methanesulfonate of formula (II) and the compound bisulfate of formula (I) alone or in combination on subcutaneous xenografts of human lung cancer H1975 nude mice;
  • the hydrogen sulfate salt of the compound represented by formula (I) is prepared by the method disclosed in WO2014194741; the mesylate salt of the compound represented by formula (II) is prepared by the method disclosed in WO2017161937. Both were formulated with 0.1% Tween80 and 0.5% CMC and diluted.
  • Human H1975 lung cancer cells were purchased from the Cell Bank of the Chinese Academy of Sciences. H1975 cells were adhered to a 10-cm petri dish and cultured under the condition that RPMI 1640 medium was supplemented with 10% fetal bovine serum and penicillin and streptomycin, and cultured in an incubator at 37 ° C and 5% CO 2 air. Passage 2-3 times a week. When the cells are in exponential growth phase, trypsinize, collect cells, count, and inoculate.
  • BALB / c nude mice, 6-7 weeks, ⁇ purchased from Shanghai Lingchang Biotechnology Co., Ltd.
  • mice were subcutaneously inoculated with 5.5 ⁇ 10 6 human H1975 lung cancer cells. After the tumor grew to 100-200 mm 3 , the animals were grouped according to tumor volume (D0). Mice were administered orally (ig) once a day (QD) or twice a day (BID); the administration volume was 10 mL / kg; the solvent group was given the same volume of "solvent" (0.1% Tween80 + 0.5% CMC); See Table 1 for specific dosages and schedules. The tumor volume was measured twice a week, the weight of the mice was weighed, and the data was recorded.
  • D0 tumor volume
  • Mice were administered orally (ig) once a day (QD) or twice a day (BID); the administration volume was 10 mL / kg; the solvent group was given the same volume of "solvent" (0.1% Tween80 + 0.5% CMC); See Table 1 for specific dosages and schedules.
  • the tumor volume was measured twice a week, the weight of the mice was
  • the experimental index is to examine the effect of the drug on tumor growth, and the specific index is T / C% or tumor inhibition rate TGI (%).
  • the tumor diameter is measured twice a week with a vernier caliper, and the tumor volume (V) calculation formula is:
  • V 1/2 ⁇ a ⁇ b 2
  • a and b represent length and width, respectively.
  • T / C (%) (T-T0) / (C-C0) ⁇ 100, where T and C are tumor volumes at the end of the experiment; T0 and C0 are tumor volumes at the beginning of the experiment.
  • Tumor inhibition rate (TGI) (%) 100-T / C (%).
  • TGI tumor inhibition rate
  • tumor partial regression PR
  • CR tumor complete regression
  • tumor tissues were taken at 2 and 8 hours after the last dose, liquid nitrogen was quickly frozen, and stored at -70 ° C for future use.
  • Drug B (5mg / kg, ig, QD ⁇ 12) inhibited the growth of human lung cancer H1975 (EGFR L858R / T790M ) subcutaneously transplanted tumors in nude mice with a tumor suppression rate of 47%; drug A (10, 30mg / kg, ig, (BID ⁇ 12)
  • the tumor inhibition rates of H1975 subcutaneously transplanted tumors were -24% and 5%, respectively; the combined tumor inhibition rates of the two increased to 70% and 90%, of which drug A 30mg / kg + drug B 5mg / kg combined group
  • the effect was significantly stronger than that of the single drug (P ⁇ 0.01, compared with the single drug); tumor-bearing mice were well tolerated by the above drugs, and no significant weight loss and other symptoms occurred.
  • the results indicate that the combination of drug A and drug B has a synergistic effect on human lung cancer H1975 subcutaneously transplanted tumors in nude mice.
  • Methanesulfonate (5 mg / kg, ig, QD ⁇ 12) of the compound represented by formula (II) inhibits the growth of human lung cancer H1975 (EGFR L858R / T790M ) subcutaneously transplanted tumors in nude mice; hydrogen sulfate of the compound represented by formula (I) Salt (10, 30mg / kg, ig, BID ⁇ 12) had no obvious effect on H1975 subcutaneous transplantation tumors; the tumor inhibition rate of the two combined treatments increased significantly (P ⁇ 0.01). The tumor-bearing mice are well tolerated by the above drugs.

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne l'utilisation d'une combinaison d'un inhibiteur de JAK kinase et d'un inhibiteur D'EGFR récepteur du facteur de croissance épidermique humain dans la préparation d'un médicament pour la prévention ou le traitement de maladies tumorales.
PCT/CN2019/105250 2018-09-12 2019-09-11 Utilisation d'une combinaison d'un inhibiteur de kinase jak et d'un inhibiteur d'egfr dans la préparation d'un médicament pour le traitement de maladies tumorales Ceased WO2020052575A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201980052669.6A CN112533606B (zh) 2018-09-12 2019-09-11 Jak激酶抑制剂与egfr抑制剂联合在制备治疗肿瘤疾病的药物中的用途

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201811060976 2018-09-12
CN201811060976.2 2018-09-12

Publications (1)

Publication Number Publication Date
WO2020052575A1 true WO2020052575A1 (fr) 2020-03-19

Family

ID=69777403

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2019/105250 Ceased WO2020052575A1 (fr) 2018-09-12 2019-09-11 Utilisation d'une combinaison d'un inhibiteur de kinase jak et d'un inhibiteur d'egfr dans la préparation d'un médicament pour le traitement de maladies tumorales

Country Status (3)

Country Link
CN (1) CN112533606B (fr)
TW (1) TWI754170B (fr)
WO (1) WO2020052575A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112933095A (zh) * 2020-12-29 2021-06-11 上海岸阔医药科技有限公司 预防或治疗egfr功能异常相关的副作用的方法
WO2022026442A1 (fr) * 2020-07-27 2022-02-03 Spectrum Pharmaceuticals, Inc. Traitement du cancer bronchique non à petites cellules avec poziotinib
WO2022143629A1 (fr) * 2020-12-29 2022-07-07 上海岸阔医药科技有限公司 Réactif et procédé pour le traitement de maladies ou d'affections cutanées associées à un agent antitumoral
CN115137832A (zh) * 2022-07-07 2022-10-04 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) 一种jak抑制剂的用途及其抗毛霉感染实验方法
EP3980046A4 (fr) * 2019-06-07 2023-04-19 Emory University Mutant g12v de kras se liant à jak1, inhibiteurs, compositions pharmaceutiques et procédés associés

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103415520A (zh) * 2011-12-21 2013-11-27 江苏恒瑞医药股份有限公司 吡咯并六元杂芳环类衍生物、其制备方法及其在医药上的应用
WO2016054987A1 (fr) * 2014-10-11 2016-04-14 上海翰森生物医药科技有限公司 Inhibiteur d'egfr, et préparation et application associées

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103415520A (zh) * 2011-12-21 2013-11-27 江苏恒瑞医药股份有限公司 吡咯并六元杂芳环类衍生物、其制备方法及其在医药上的应用
WO2016054987A1 (fr) * 2014-10-11 2016-04-14 上海翰森生物医药科技有限公司 Inhibiteur d'egfr, et préparation et application associées

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WEI WEN ET AL: "Synergistic anti-tumor effect of combined inhibition of EGFR and JAK/STAT3 pathways in human overian cancer", MOLECULAR CANCER, vol. 14, no. 1, 1 May 2015 (2015-05-01), pages 100, XP021223019, ISSN: 1476-4598 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3980046A4 (fr) * 2019-06-07 2023-04-19 Emory University Mutant g12v de kras se liant à jak1, inhibiteurs, compositions pharmaceutiques et procédés associés
US12577278B2 (en) 2019-06-07 2026-03-17 Emory University KRAS G12V mutant binds to JAK1, inhibitors, pharmaceutical compositions, and methods related thereto
WO2022026442A1 (fr) * 2020-07-27 2022-02-03 Spectrum Pharmaceuticals, Inc. Traitement du cancer bronchique non à petites cellules avec poziotinib
CN112933095A (zh) * 2020-12-29 2021-06-11 上海岸阔医药科技有限公司 预防或治疗egfr功能异常相关的副作用的方法
WO2022143630A1 (fr) * 2020-12-29 2022-07-07 上海岸阔医药科技有限公司 Procédé de prévention ou de traitement d'effets secondaires associés à des dysfonctionnements de l'egfr
WO2022143629A1 (fr) * 2020-12-29 2022-07-07 上海岸阔医药科技有限公司 Réactif et procédé pour le traitement de maladies ou d'affections cutanées associées à un agent antitumoral
CN116635026A (zh) * 2020-12-29 2023-08-22 上海岸阔医药科技有限公司 治疗与抗肿瘤剂相关的皮肤疾病或病症的试剂和方法
CN116669765A (zh) * 2020-12-29 2023-08-29 上海岸阔医药科技有限公司 预防或治疗egfr功能异常相关的副作用的方法
CN115137832A (zh) * 2022-07-07 2022-10-04 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) 一种jak抑制剂的用途及其抗毛霉感染实验方法
CN115137832B (zh) * 2022-07-07 2023-11-17 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) 一种jak抑制剂的用途及其抗毛霉感染实验方法

Also Published As

Publication number Publication date
TW202024067A (zh) 2020-07-01
TWI754170B (zh) 2022-02-01
CN112533606A (zh) 2021-03-19
CN112533606B (zh) 2023-04-04

Similar Documents

Publication Publication Date Title
CN112533606B (zh) Jak激酶抑制剂与egfr抑制剂联合在制备治疗肿瘤疾病的药物中的用途
CN113301895B (zh) 多靶点酪氨酸激酶抑制剂与egfr抑制剂联合在制备治疗肿瘤的药物中的用途
US11291667B2 (en) Combination therapy involving diaryl macrocyclic compounds
US10646470B2 (en) Uses of indolinone compounds
CN111818925B (zh) Cdk4/6抑制剂与egfr抑制剂联合在制备治疗肿瘤疾病的药物中的用途
WO2019057141A1 (fr) Utilisation de l'apatinib en association avec un inhibiteur de c-met dans la préparation d'un médicament pour le traitement de tumeurs
TW202435855A (zh) 包含阿茲夫定的抗腫瘤藥物組合物
CN110292578A (zh) 阿帕替尼在制备治疗急性髓系白血病的药物中的新应用
US20130324520A1 (en) Rxrg modulators for the treatment of cancer
JPWO2009028387A1 (ja) プロテアーゼ阻害剤耐性を有する癌の治療薬
WO2022063220A1 (fr) Composition pharmaceutique et son utilisation dans le traitement du cancer
WO2006077793A1 (fr) Agent antitumoral
US20220315587A1 (en) Compounds for treatment of cancer
WO2021160147A1 (fr) Utilisation d'un composé de pyrido[1,2-a]pyrimidinone dans le traitement du lymphome
CN118510518A (zh) 包括吡啶并[1,2-a]嘧啶酮化合物和EGFR抑制剂的药物组合
WO2020254299A1 (fr) Combinaison d'un inhibiteur de mcl-1 et d'un standard de traitement de soin pour cancers du sein, utilisations et compositions pharmaceutiques associées
WO2024120461A1 (fr) Utilisation d'inducteurs de cyp3a4/5 dans le traitement ou le soulagement d'une neuropathie périphérique
CN120659608A (zh) 用于治疗癌症的tead抑制剂和kras g12d抑制剂组合
WO2023020291A1 (fr) Utilisation combinée de l'in10018 et de la pld
CN114569619A (zh) Pi3k抑制剂单用或联合egfr抑制剂在制备治疗头颈癌或胃癌的药物中的用途
TW202200136A (zh) 癌治療方法
CN121059810A (zh) Ezh2抑制剂联合jak抑制剂在制备治疗肿瘤药物中的用途
US20240238220A1 (en) Methods for treating cancers
Al-Odat Selective Small Molecule Targeting of MCL-1 in Multiple Myeloma
TW202404598A (zh) 用於具有突變之癌症之組合物及治療

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19859193

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19859193

Country of ref document: EP

Kind code of ref document: A1